`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`APOTEX CORP.,
`Petitioner
`
`v.
`
`ALCON RESEARCH, LTD.,
`Patent Owner.
`
`
`Case IPR2013-00428
`U.S. Patent No. 8,268,299 B2
`
`
`
`
`ALCON RESEARCH, LTD.’S MOTION TO SEAL AND MOTION FOR
`ENTRY OF PROPOSED PROTECTIVE ORDER
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Attorney Docket No.
`
`Case IPR2013-00428
`PAT903205-US-NP
`
`U.S. Patent No. 8,268,299
`Pursuant to 37 C.F.R. §§ 42.14 and 42.54, Patent Owner Alcon Research,
`
`Ltd. (“Alcon”) hereby respectfully moves to seal confidential laboratory notebooks
`
`and adjunctive data (Exhibits AL 2059—2073), portions of the Declaration of Dr.
`
`Henry Grabowski, Ph.D. (Exhibit AL 2007), and certain exhibits on which Dr.
`
`Grabowski relied in forming his opinions (Exhibits AL 2032–2042). In support of
`
`this Motion, Alcon is also submitting a proposed protective order (Exhibit AL
`
`2056). See 37 C.F.R. § 42.54(a). Petitioner Apotex Corp. (“Apotex”) does not
`
`oppose the motion and agrees to the proposed protective order.
`
`A. Motion to Seal
`The standard for granting a motion to seal is “for good cause.” 37 C.F.R.
`
`§ 42.54; Decision – Revised Motion to Seal, Garmin Int’l, Inc. v. Cuozzo Speed
`
`Techs. LLC, Case IPR2012-00001 (JL), at 4 (Apr. 5, 2013) (hereinafter Garmin
`
`Decision). Good cause exists for sealing these exhibits.
`
`Laboratory notebooks and adjunctive data
`
`1.
`Exhibits AL 2059–2073 are excerpts of confidential laboratory notebooks
`
`and adjunctive data used by Alcon employees to record their research and
`
`development work. These documents are being submitted in support of affidavits
`
`filed pursuant to 37 C.F.R. § 42.61 describing how certain data in the
`
`specifications of Alcon patents were generated. Although the data on which Alcon
`
`relies in this proceeding are disclosed in public patent specifications, the
`
`
`
`2
`
`
`
`Attorney Docket No.
`
`Case IPR2013-00428
`PAT903205-US-NP
`
`U.S. Patent No. 8,268,299
`documents Alcon proposes to seal also disclose internal Alcon laboratory methods
`
`and practices and additional, unpublished testing data. Public disclosure of these
`
`confidential, internal documents reflecting Alcon’s research and development work
`
`has the potential to cause Alcon competitive harm.
`
`Because the data on which Alcon relies in this proceeding are already in the
`
`public record, the public’s interest in having access to these documents in order to
`
`“maintain a complete and understandable file history” is minimal. Garmin
`
`Decision at 8 (balancing need for confidentiality against public’s interest).
`
`Moreover, pursuant to 37 C.F.R. § 42.61, these documents are being submitted in
`
`conjunction with the declarations of Bhagwati Kabra, Ph.D., and Stephen Shannon,
`
`MBA, Ph.D. Dr. Kabra’s and Dr. Shannon’s declarations explain the testing data
`
`in the patent specification, explain in general the significance of the laboratory
`
`notebooks and adjunctive data, and are not being filed under seal. Accordingly, a
`
`“complete and understandable file history” will be available to the public even if
`
`these exhibits are sealed.
`
`Summaries of IMS Health and Encuity Research Data
`
`2.
`Exhibits AL 2032–2042 summarize data provided to Alcon by IMS Health
`
`and Encuity Research. These exhibits contain data on sales, units, prescriptions,
`
`and promotional spending for a number of pharmaceutical products. These data
`
`were provided by IMS Health and Encuity Research to counsel for Alcon pursuant
`
`
`
`3
`
`
`
`Attorney Docket No.
`
`Case IPR2013-00428
`PAT903205-US-NP
`
`U.S. Patent No. 8,268,299
`to agreements to keep the data confidential. It is undersigned counsel’s
`
`understanding that IMS Health and Encuity Research charge customers for these
`
`data, that they do not make their data generally available to the public, and that
`
`they would be harmed by the public disclosure of these data without a
`
`confidentiality agreement.
`
`The public’s interest in having access to these exhibits is minimal. See
`
`Garmin Decision at 8. These exhibits are being provided in support of the
`
`declaration of Dr. Henry Grabowski, Ph.D. In conjunction with this motion, Alcon
`
`is submitting a non-confidential, redacted version of Dr. Grabowski’s declaration.
`
`The substance of Dr. Grabowski’s opinions can be fully ascertained from the
`
`redacted declaration; the only information not reflected in the redacted declaration
`
`is data from IMS Health and Encuity Research and Dr. Grabowski’s specific
`
`calculations based on that data. Moreover, interested members of the public can
`
`obtain the data in question directly from IMS Health and Encuity Research
`
`(presumably for a fee).
`
`Dr. Grabowski’s Declaration
`
`3.
`Exhibit AL 2007 is the declaration of Dr. Henry Grabowski, Ph.D. This
`
`exhibit discloses data (and calculations derived therefrom) obtained from IMS
`
`Health and Encuity Research. As explained above, good cause exists to seal these
`
`data, see supra Part A.2, and for the same reasons, good cause exists to seal the
`
`
`
`4
`
`
`
`Attorney Docket No.
`
`Case IPR2013-00428
`PAT903205-US-NP
`
`U.S. Patent No. 8,268,299
`portions of Dr. Grabowski’s declaration which disclose these data or calculations
`
`derived therefrom.
`
`Proposed Protective Order
`
`B.
`Pursuant to 37 C.F.R. § 42.54, Alcon is submitting a proposed protective
`
`order, attached hereto as Exhibit AL 2056. Alcon requests that the proposed
`
`protective order be entered and that its terms govern the confidentiality of the
`
`exhibits which are the subject of this motion.
`
`The proposed protective order is based on the PTAB’s default order, but the
`
`parties have agreed to modify it in three ways intended to minimize the
`
`administrative burdens of complying with the order. First, party representatives
`
`need not sign an acknowledgment to have access to confidential materials.
`
`Second, party representatives include not only counsel of record, but also other
`
`attorneys working at the firms of Williams & Connolly LLP and Sterne, Kessler,
`
`Goldstein & Fox PLLC. Third, persons who receive confidential information need
`
`not maintain a record of the locations of copies of that information.
`
`C. Certification of Conference with Opposing Party Pursuant to 37
`C.F.R. § 42.54
`
`Alcon certifies that it has conferred with Apotex regarding this motion and
`
`the scope of the proposed protective order, and that Apotex does not oppose this
`
`motion and agrees to the terms of the proposed protective order.
`
`
`
`5
`
`
`
`Case IPR2013-00428
`U.S. Patent No. 8,268,299
`D. Conclusion
`For the foregoing reasons, Alcon respectfully requests that its motion to seal
`
`Attorney Docket No.
`PAT903205-US-NP
`
`
`
`
`be granted and that the PTAB enter the proposed protective order.
`
`Dated: March 27, 2014
`
`Respectfully submitted,
`
`/Stanley E. Fisher/
`Stanley E. Fisher
`Reg. No. 55,820
`Phone: 202-434-5289
`
`
`
`Correspondence Address:
`Williams & Connolly LLP
`725 Twelfth Street NW
`Washington, D.C. 20005
`
`
`
`6
`
`
`
`Attorney Docket No.
`
`Case IPR2013-00428
`PAT903205-US-NP
`
`U.S. Patent No. 8,268,299
`CERTIFICATE OF SERVICE (37 C.F.R. § 42.6(e))
`
`The undersigned hereby certifies that the foregoing “ALCON RESEARCH,
`
`LTD.’S MOTION TO SEAL AND MOTION FOR ENTRY OF PROPOSED
`
`PROTECTIVE ORDER” was served on March 27, 2014, by filing this document
`
`through the Patent Review Processing System as well as delivering a copy via
`
`electronic mail to the following attorneys of record for the Petitioner:
`
`Eldora L. Ellison (Reg. No. 39,967)
`Ralph W. Powers III (Reg. No. 63,504)
`Sterne, Kessler, Goldstein & Fox P.L.L.C.
`1100 New York Avenue, NW
`Washington, DC 20005
`(202) 371-2600 (telephone)
`(202) 371-2540 (facsimile)
`eellison-PTAB@skgf.com
`tpowers-PTAB@skgf.com
`
`
`
`
`
`Dated: March 27, 2014
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Respectfully submitted,
`
`/Stanley E. Fisher/
`Stanley E. Fisher
`Reg. No. 55,820
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`7
`
`